REG - Immupharma PLC - Result of AGM

ImmuPharmaAnnouncement

28/06/2024 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240628:nRSb3931Ua&default-theme=true

RNS Number : 3931U  Immupharma PLC  28 June 2024

 

 

RNS:
RELEASE
      28 June 2024

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2024 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, held its AGM earlier today. The Company is pleased to announce that
all resolutions were duly passed, details of which are contained in the table
below.

 

 

 

 Resolution                                                                       For         % For   Against    % Against  Withheld
 1. To receive the accounts of the Company for the year ended 31 December 2023    86,062,471  100%    2,400      0.00%      11,950
 together with the reports thereon of the directors and auditors of the Company
 2. To re-appoint Dr Laurence Reilly as a director of the Company                 80,641,856  97.22%  2,305,727  2.78%      3,129,241
 3. To re-appoint Dr Sebastian Goudreau as a director of the Company              82,355,053  97.28%  2,305,727  2.72%      1,416,044
 4. To re-appoint Lisa Baderoon as a director of the Company                      82,357,053  97.28%  2,305,727  2.72%      1,414,044
 5. To re-appoint CLA Evelyn Partners Limited as Auditor of the Company           81,844,124  97.25%  2,318,324  2.75%      1,914,376
 6. That the Directors be authorised for the purpose of Section 551 of the        81,127,174  95.26%  4,040,309  4.74%      909,338
 Companies Act 2006 (the "Act") to allot shares on the basis as set out in the
 Notice of Meeting
 SPECIAL RESOLUTION                                                               81,127,174  95.26%  4,040,309  4.74%      909,338
 7. That, subject to the passing of Resolution 6 the directors be and they are
 hereby empowered pursuant to section 571 of the Act to allot equity securities
 as set out in the Notice of Meeting

 

 

As at the date of the AGM, the number of issued ordinary shares of the Company
was 416,437,265 shares, which was the total number of shares entitling the
holders to attend and vote for or against all resolutions. In accordance with
the Company's Articles of Association, every member has one vote for every
share held. Votes withheld are not votes in law and have not been counted in
the calculation of the proportion of vote "for" or "against" a
resolution. Proxy appointments which gave discretion to the Chairman have
been included in the "for" total.

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

Ends

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer and Chairman

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650/51

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 is a first-in class autophagy
immunomodulator for the treatment of Lupus and CIDP and preclinical analysis
suggests P140 may have therapeutic benefit in many other autoimmune diseases
that are caused by the same dysfunction in the immune system.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(https://www.immupharma.co.uk/)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGMZGZVMRFGDZM